Evidence map›Paper›PMID 35245585›Full record

ArticleThe Journal of infection2022

Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.

Wing Ying Au, Chengjin Ye, Sydney Leigh Briner, Gianmarco Domenico Suarez, Jeewon Han, Xinzhou Xu, Jun-Gyu Park, Melinda Ann Brindley, Luis Martinez-Sobrido, Peter Pak-Hang Cheung

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Wing Ying AuDepartment of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Li Ka Shing Medical Sciences Building, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
Chengjin YeTexas Biomedical Research Institute, San Antonio, Texas, U.S.A.
Sydney Leigh BrinerDepartment of Infectious Diseases, Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, Georgia, U.S.A.
Gianmarco Domenico SuarezDepartment of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.
Jeewon HanDepartment of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.
Xinzhou XuDepartment of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Li Ka Shing Medical Sciences Building, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
Jun-Gyu ParkTexas Biomedical Research Institute, San Antonio, Texas, U.S.A.
Melinda Ann BrindleyDepartment of Infectious Diseases, Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, Georgia, U.S.A.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, Texas, U.S.A.. Electronic address: lmartinez@txbiomed.org.
Peter Pak-Hang CheungDepartment of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Li Ka Shing Medical Sciences Building, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China. Electronic address: ppcheung@cuhk.edu.hk.
Chinese University of Hong Kong · HKTexas Biomedical Research Institute · USHong Kong University of Science and Technology · HKUniversity of Georgia · US

Funding

Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2R01AI161363 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GUPTA, YOGESH K · 2021 to 2025
$3.2M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Developing a Thermostable SARS-CoV-2 RBD-particle VaccineR43AI165089 · NIAID · POP BIOTECHNOLOGIES, INC · PI HUANG, WEI-CHIAO · 2021 to 2022
$600k
NIAID NIH HHS R01 AI161175NIAID NIH HHS R01 AI161363
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesHumansAntibodies, ViralBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID35245585
PMCPMC8889726
OpenAlexW4214899210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.